CAR1922T2 T cells / Tongji Hospital - LARVOL DELTA

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Tongji Hospital | Trial completion date: Oct 2027 ➔ Feb 2029 | Initiation date: Mar 2025 ➔ Feb 2026 | Trial primary completion date: Oct 2027 ➔ Feb 2028

Trial completion date • Trial initiation date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Tongji Hospital

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology